

EXHIBIT 295

1 IN THE UNITED STATES DISTRICT COURT
2 FOR THE NORTHERN DISTRICT OF OHIO
3 EASTERN DIVISION
4 - - -
5

6 IN RE: NATIONAL : MDL NO. 2804
7 PRESCRIPTION OPIATE :
8 LITIGATION :
9 :-----
10 :

11 -----
12 THIS DOCUMENT RELATES TO : CASE NO.
13 ALL CASES : 1:17-MD-2804
14 :
15 : Hon. Dan A.
16 : Polster
17 - - -
18 February 8, 2019
19 - - -

20 HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
21 CONFIDENTIALITY REVIEW
22

23 Continued videotaped deposition
24 of STEPHEN MAYS taken pursuant to notice, was
25 held at the law offices of Reed Smith LLP, Three
26 Logan Square, 1717 Arch Street, Suite 3100,
27 Philadelphia, Pennsylvania, beginning at 11:12
28 a.m., on the above date, before Ann Marie
29 Mitchell, a Federally Approved Certified Realtime
30 Reporter, Registered Diplomate Reporter,
31 Registered Merit Reporter and Notary Public.

32 - - -
33 GOLKOW LITIGATION SERVICES
34 877.370.3377 ph | 917.591.5672 fax
35 deps@golkow.com
36

Page 2	Page 4
<p>1 APPEARANCES:</p> <p>3 BARON & BUDD, P.C. BY: MARK PIFKO, ESQUIRE 4 15910 Ventura Boulevard Suite 1600 5 Encino, California 91436 (818) 839-2333 6 mpifko@baronbudd.com Representing the Plaintiffs</p> <p>8</p> <p>9 BARON & BUDD, P.C. BY: WILLIAM POWERS, ESQUIRE 10 600 New Hampshire Avenue NW The Watergate, Suite 10-A Washington, DC 20037 11 (202) 333-4562 12 wpowers@baronbudd.com Representing the Plaintiffs</p> <p>13</p> <p>14 REED SMITH LLP BY: SHANNON E. MCCLURE, ESQUIRE BY: JEFFREY R. MELTON, ESQUIRE BY: ABIGAIL M. PIERCE, ESQUIRE Three Logan Square 1717 Arch Street, Suite 3100 17 Philadelphia, Pennsylvania 19103 (215) 851-8100 18 smcclure@reedsmith.com jmelton@reedsmith.com 19 abigail.pierce@reedsmith.com Representing AmerisourceBergen Drug 20 Corporation</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>1 APPEARANCES VIA TELEPHONE/STREAM:</p> <p>3 BARON & BUDD, P.C. BY: W. SCOTT SIMMER, ESQUIRE 4 BY: GRETCHEN KEARNEY, ESQUIRE 600 New Hampshire Avenue NW 5 The Watergate, Suite 10-A Washington, DC 20037 6 (202) 333-4562 7 ssimmer@baronbudd.com gkearney@baronbudd.com Representing Plaintiffs</p> <p>8</p> <p>9</p> <p>10 BARON & BUDD, P.C. BY: STERLING CLUFF, ESQUIRE 11 BY: JAY LICHTER, ESQUIRE 15910 Ventura Blvd Suite 1600 12 Encino, California 91436 (818) 839-2333 13 cluff@baronbudd.com jlichter@baronbudd.com Representing the Plaintiffs</p> <p>14</p> <p>15 GREENE KETCHUM FARRELL BAILEY & TWEEL LLP BY: PAUL THOMAS FARRELL JR., ESQUIRE 17 419 Eleventh Street Huntington, West Virginia 25701 18 (304) 525-9115 Representing the Plaintiffs</p> <p>19</p> <p>20</p> <p>21 THE LANIER LAW FIRM BY: EVAN M. JANUSH, ESQUIRE Tower 56 22 126 East 56th Street, 6th Floor New York, New York 10022 23 (212) 421-2800 evan.janush@lanierlawfirm.com Representing the Plaintiffs</p> <p>24</p>
Page 3	Page 5
<p>1 APPEARANCES (cont.'d):</p> <p>3 JONES DAY BY: ADAM HOLLINGSWORTH, ESQUIRE 4 North Point 901 Lakeside Avenue 5 Cleveland, Ohio 44114 (216) 586-3939 6 ahollingsworth@jonesday.com Representing Walmart</p> <p>7</p> <p>8 COVINGTON & BURLING, LLP BY: MEGHAN E. MONAGHAN, ESQUIRE 10 One City Center, 850 Tenth Street, NW Washington, DC 20001 (202) 662-5272 11 mmonaghan@cov.com Representing McKesson Corporation</p> <p>12</p> <p>13 WILLIAMS & CONNOLLY LLP BY: KATELYN ADAMS, ESQUIRE 725 Twelfth Street, N.W. 15 Washington, DC 20005 kadams@wc.com (202) 434-5000 16 Representing Cardinal Health</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>1 APPEARANCES VIA TELEPHONE/STREAM (cont.'d):</p> <p>3 BLASINGAME, BURCH, GARRARD & ASHLEY, P.C. BY: ALEXANDRA K. HUGHES, ESQUIRE 4 440 College Avenue Suite 320 5 Athens, Georgia 30601 (706) 744-4135 6 ahughes@bbga.com Representing the Plaintiffs</p> <p>7</p> <p>8</p> <p>9 BAILEY & WYANT, PLLC BY: HARRISON M. CYRUS, ESQUIRE 500 Virginia Street East 10 Suite 600 Charleston, West Virginia 25301 (304) 345-4222 11 hcyrus@baileywyant.com Representing the West Virginia Board of Pharmacy</p> <p>12</p> <p>13 REED SMITH LLP BY: ANNE E. ROLLINS, ESQUIRE Three Logan Square 15 1717 Arch Street, Suite 3100 Philadelphia, Pennsylvania 19103 (215) 851-8100 17 arollins@reedsmith.com Representing AmerisourceBergen Drug Corporation</p> <p>18</p> <p>19</p> <p>20 ROPES & GRAY LLP BY: LUKE D. RILEY, ESQUIRE Prudential Tower 800 Boylston Street 21 Boston, Massachusetts 02199 (617) 951-7000 22 luke.riley@ropesgray.com Representing Mallinckrodt</p> <p>23</p> <p>24</p>

Page 6		Page 8
1 APPEARANCES VIA TELEPHONE/STREAM (cont.'d):	1	
2	2	- - - I N D E X
3 ARNOLD & PORTER KAYE SCHOLER LLP	3	
BY: ZENO HOUSTON, ESQUIRE	4	
250 West 55th Street	5	Testimony of: STEPHEN MAYS
New York, New York 10019	6	By Mr. Pifko 12
(212) 836-8000	7	
zeno.houston@arnoldporter.com	8	- - -
Representing Endo Health Solutions; Endo	9	E X H I B I T S
Pharmaceuticals, Inc.; Par Pharmaceutical	10	
Companies, Inc. f/k/a Par Pharmaceutical	11	- - -
Holdings, Inc.	12	
13	13	
14 BARNES & THORNBURG LLP	14	
15 BY: MONIQUE HANNAM, ESQUIRE	15	NO. DESCRIPTION PAGE
16 11 South Meridian Street	16	Mays V2-1 Order to Show Cause and 17
17 Indianapolis, Indiana 46204	17	Immediate Suspension of
(317) 236-1313	18	Registration, Bates
19 monique.hannam@btlaw.com	19	stamped ABDCMDL00269383
20 Representing HD Smith	20	through ABDCMDL00269387
21	21	Mays V2-2 Email chain, top one dated 91
22 VIDEOGRAPHER:	22	3 Mar 2013, Bates stamped
23 DAVID LANE	23	ABDCMDL00378483 through
24 TRIAL TECHNICIAN:	24	ABDCMDL00378488
25 ZACH HONE	18	Mays V2-3 Email chain, top one dated 99
26 ALSO PRESENT:	19	2/6/2008, Bates stamped
27 CHRISTOPHER CASALENUOVO, ESQUIRE	20	CAH_MDL2804_01364805
28 AmerisourceBergen Drug Corporation	21	through
29 ALSO PRESENT VIA TELEPHONE/STREAM:	22	CAH_MDL2804_01364809
30	23	
31 TIFFANY ELLIS	24	
32 Weitz & Luxenberg P.C.	1	
	2	- - -
	3	DEPOSITION SUPPORT INDEX
	4	
	5	- - -
	6	Direction to Witness Not to Answer
	7	
	8	Page Line
	9	
	10	Request for Production of Documents
	11	
	12	Page Line
	13	
	14	Stipulations
	15	
	16	Page Line
	17	
	18	Question Marked
	19	
	20	Page Line
	21	
	22	
	23	
	24	

Page 10	Page 12
<p>1 THE VIDEOGRAPHER: We're now on 2 the record. My name is David Lane, 3 videographer for Golkow Litigation 4 Services. Today's date is 11:12 a.m. 5 This deposition is taking place in 6 Philadelphia, Pennsylvania in the matter 7 of National Prescription Opiate 8 Litigation MDL.</p> <p>9 Our deponent today is Steve Mays. 10 All counsel will be noted on the 11 stenographic record.</p> <p>12 The court reporter is Ann Marie 13 Mitchell, who will now swear in our 14 witness.</p> <p>15 - - -</p> <p>16 STEPHEN MAYS, after having been 17 duly sworn, was examined and testified as 18 follows:</p> <p>19 - - -</p> <p>20 THE VIDEOGRAPHER: Please begin.</p> <p>21 MR. PIFKO: Could we get everyone 22 to state their appearance, or did people 23 already do that?</p> <p>24 Mark Pifko from Baron & Budd on</p>	<p>1 Arnold & Porter on behalf of Endo and 2 Par.</p> <p>3 MR. FARRELL: Paul Farrell on 4 behalf of the PEC.</p> <p>5 COURT REPORTER: Counsel?</p> <p>6 MS. McCLURE: Paul? Hey, Paul, 7 you're going to have to restate that. I 8 could hear your name vaguely, but the 9 court reporter and the videographer could 10 not hear you.</p> <p>11 MR. FARRELL: This is Paul 12 Farrell, Jr., for the PEC. And I will be 13 on for portions of today but not the 14 entire duration.</p> <p>15 MR. PIFKO: All right.</p> <p>16 - - -</p> <p>17 EXAMINATION</p> <p>18 - - -</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. Ready to begin?</p> <p>21 A. Yes, sir.</p> <p>22 Q. You understand that you're under 23 oath.</p>
<p>1 behalf of the plaintiffs and the PEC.</p> <p>2 MR. POWERS: Will Powers, also 3 from Baron & Budd.</p> <p>4 MS. McCLURE: Shannon McClure on 5 behalf of ABDC.</p> <p>6 MR. MELTON: Jeffrey Melton on 7 behalf of ABDC.</p> <p>8 MR. CASALENUOVO: Chris 9 Casalenuovo with ABDC.</p> <p>10 MS. PIERCE: Abigail Pierce, 11 Reed.</p> <p>12 MS. MONAGHAN: Meghan Monaghan 13 for McKesson.</p> <p>14 MS. ADAMS: Kate Adams for 15 Cardinal Health.</p> <p>16 MR. HOLLINGSWORTH: Adam 17 Hollingsworth on behalf of Walmart.</p> <p>18 THE VIDEOGRAPHER: Counsel on the 19 phone?</p> <p>20 MS. HANNAM: This is Monique 21 Hannam on behalf of HD Smith.</p> <p>22 MR. RILEY: Luke Riley on behalf 23 of Ropes & Gray.</p> <p>24 MR. HOUSTON: Zeno Houston from</p>	<p>1 A. Yes, sir.</p> <p>2 Q. Correct?</p> <p>3 Okay. And that means that you 4 are under penalty of perjury. And if you are 5 intentionally dishonest or misleading, that you 6 could be subject to penalties from the court.</p> <p>7 Do you understand that?</p> <p>8 A. I understand.</p> <p>9 Q. Okay. Is there any reason why 10 you're unable to give truthful and accurate 11 testimony today?</p> <p>12 A. No.</p> <p>13 Q. Are you undergoing any medical 14 treatment or taking any medications that would 15 impact your ability to tell the truth?</p> <p>16 A. No.</p> <p>17 Q. Are you undergoing any treatment 18 or taking any medication that would impact your 19 memory?</p> <p>20 A. No.</p> <p>21 Q. Is there any reason why this 22 deposition shouldn't go forward, as far as you 23 know?</p> <p>24 A. As far as I know.</p>

<p style="text-align: right;">Page 14</p> <p>1 Q. Okay. So you were deposed a few 2 months ago or so in this case. 3 Do you recall? 4 A. I do. 5 Q. Okay. One of the things we 6 discussed in your prior deposition was your work 7 history with your current employer. 8 Do you recall that? 9 A. Yes. 10 Q. During your last deposition, we 11 discussed how one of the things that you did was 12 you established the Orlando facility for the 13 company. 14 Do you recall that discussion? 15 MS. McCLURE: Objection to form. 16 THE WITNESS: I didn't establish 17 it alone. I was the operations manager. 18 BY MR. PIFKO: 19 Q. Okay. 20 A. When it was opened, yes. 21 Q. But you were one of the people 22 who was responsible for establishing the Orlando 23 facility. Correct? 24 A. That's right.</p>	<p style="text-align: right;">Page 16</p> <p>1 was the most senior role. 2 BY MR. PIFKO: 3 Q. And then later you became an 4 auditor. Correct? 5 A. Yes. 6 Q. And part of your responsibilities 7 involved auditing the facilities, including the 8 Orlando facility. Correct? 9 A. Originally not the Orlando 10 facility. 11 Q. But ultimately you did have 12 responsibilities that included auditing the 13 Orlando facility. Correct? 14 A. I believe -- 15 MS. McCLURE: Objection, asked 16 and answered. 17 THE WITNESS: I believe that was 18 in my area of responsibility, yes. 19 BY MR. PIFKO: 20 Q. Are you familiar with the order 21 to show cause that was issued concerning the 22 Orlando facility? 23 A. Yes. 24 MS. McCLURE: Objection, asked</p>
<p style="text-align: right;">Page 15</p> <p>1 MS. McCLURE: Objection to form. 2 BY MR. PIFKO: 3 Q. You moved from, I believe you 4 were in Kentucky or Tennessee? 5 A. Tennessee. 6 Q. Okay. Tennessee. You moved from 7 there to Orlando in order to help establish the 8 Orlando facility. Correct? 9 A. That's correct. 10 Q. And then you -- what was your 11 first role at the Orlando facility? 12 MS. McCLURE: Objection, asked 13 and answered. 14 THE WITNESS: I was the 15 operations manager. 16 BY MR. PIFKO: 17 Q. And did you have that role the 18 whole time that you were there? 19 A. Not the whole time, no. 20 Q. What was your most senior role 21 when you left the Orlando facility? 22 MS. McCLURE: Objection, asked 23 and answered, form. 24 THE WITNESS: Operations manager</p>	<p style="text-align: right;">Page 17</p> <p>1 and answered. 2 Are we doing a continuation of 3 the exhibit numbering? 4 MR. PIFKO: We're calling it 5 Volume 2. 6 MS. McCLURE: Thank you. 7 - - - 8 (Deposition Exhibit No. Mays 9 V2-1, Order to Show Cause and Immediate 10 Suspension of Registration, Bates stamped 11 ABDCMDL00269383 through ABDCMDL00269387, 12 was marked for identification.) 13 - - - 14 BY MR. PIFKO: 15 Q. I'm handing you what's marked as 16 Exhibit 1. Volume 2, Exhibit 1. 17 For the record, it's a letter 18 from the DEA dated April 19, 2007, Bates labeled 19 ABDCMDL00269383 through 387. 20 Have you seen this exhibit 21 before? 22 MS. McCLURE: The document or the 23 exhibit? 24 THE WITNESS: I've seen this</p>

Page 18	Page 20
<p>1 document before, yes.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. Can you tell me what this is?</p> <p>4 A. It is an order to show cause and</p> <p>5 immediate suspension of the Orlando registration.</p> <p>6 Q. When was the last time you saw</p> <p>7 this document?</p> <p>8 A. I can't recall.</p> <p>9 Q. Is this something that you</p> <p>10 reviewed in preparing for your deposition?</p> <p>11 A. No.</p> <p>12 Q. Okay. Do you believe you saw</p> <p>13 this on or around the time it was issued in April</p> <p>14 of 2007?</p> <p>15 MS. McCLURE: Objection to form.</p> <p>16 THE WITNESS: Sometime after the</p> <p>17 suspension. I didn't see it immediately.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Okay. But sometime on or</p> <p>20 around -- it was -- after it was issued, it was</p> <p>21 provided to you. Correct?</p> <p>22 A. That's correct.</p> <p>23 Q. Who would have provided it to</p> <p>24 you?</p>	<p>1 order to show cause?</p> <p>2 MS. McCLURE: Objection to form.</p> <p>3 THE WITNESS: I'm not sure what</p> <p>4 that -- I'm not sure what you mean by</p> <p>5 changes operationally.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Well, let's go through and see --</p> <p>8 let's look at Exhibit 1 and see what the</p> <p>9 Department of Justice said to AmerisourceBergen</p> <p>10 in this letter.</p> <p>11 It said, "Respondent" -- you see</p> <p>12 on the first page here, there's a number of</p> <p>13 paragraphs, starting about halfway down.</p> <p>14 It says, "Respondent has failed</p> <p>15 to maintain effective controls against diversion</p> <p>16 of particular controlled substances into other</p> <p>17 than legitimate medical, scientific and</p> <p>18 industrial channels, in violation of 21 U.S.C.</p> <p>19 Sections 823(b)(1) and (e)(1)."</p> <p>20 Do you see that?</p> <p>21 A. I do.</p> <p>22 Q. Did I read that correctly?</p> <p>23 A. I believe you did.</p> <p>24 Q. And then it says, "From January</p>
Page 19	Page 21
<p>1 MS. McCLURE: Objection to form.</p> <p>2 THE WITNESS: I don't recall.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. Were you part of discussions</p> <p>5 about what was going to be done to respond to</p> <p>6 this order to show cause?</p> <p>7 MS. McCLURE: Objection to form.</p> <p>8 THE WITNESS: Internally or with</p> <p>9 DEA?</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. Internally.</p> <p>12 A. Internally. Yes. I was part of</p> <p>13 some discussions, yes.</p> <p>14 Q. Who did you discuss this order to</p> <p>15 show cause with?</p> <p>16 A. My boss, Chris Zimmerman.</p> <p>17 Q. Anyone else?</p> <p>18 A. Not that I remember.</p> <p>19 Q. What was the nature of your</p> <p>20 discussion with Mr. Zimmerman?</p> <p>21 A. I don't recall exactly.</p> <p>22 Q. Did you discuss that you were</p> <p>23 going to make any changes to the operations at</p> <p>24 the Orlando facility as a result of seeing this</p>	<p>1 1, 2006, through January 31, 2007, Respondent</p> <p>2 distributed over 3.8 million dosage units of</p> <p>3 combination hydrocodone products to customers</p> <p>4 that it knew or should have known were diverting</p> <p>5 the hydrocodone into other than legitimate</p> <p>6 medical, scientific and industrial channels."</p> <p>7 Do you see that?</p> <p>8 A. Yes, I do.</p> <p>9 Q. Did I read that correctly?</p> <p>10 A. I think you did.</p> <p>11 Q. Did you understand at the time</p> <p>12 that that was a concern raised by the Department</p> <p>13 of Justice with respect to AmerisourceBergen?</p> <p>14 A. Yes, I understand that.</p> <p>15 MS. McCLURE: Objection to the</p> <p>16 form.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Did you have an understanding</p> <p>19 about what the specific basis was for that</p> <p>20 concern?</p> <p>21 MS. McCLURE: Objection to the</p> <p>22 form.</p> <p>23 THE WITNESS: Can you repeat that</p> <p>24 question again?</p>

<p style="text-align: right;">Page 22</p> <p>1 BY MR. PIFKO:</p> <p>2 Q. So it says here that</p> <p>3 AmerisourceBergen failed to maintain effective</p> <p>4 controls against diversion. And then it says</p> <p>5 that AmerisourceBergen distributed over</p> <p>6 3.8 million dosage units of combination</p> <p>7 hydrocodone products to customers that it knew or</p> <p>8 should have known were diverting them.</p> <p>9 Did I read that -- summarize it</p> <p>10 correctly?</p> <p>11 A. I just asked you to repeat the</p> <p>12 question.</p> <p>13 Q. Yeah. Did I summarize that</p> <p>14 correctly?</p> <p>15 A. I think you did.</p> <p>16 Q. Okay. So my question is, do you</p> <p>17 have an understanding about the specific basis of</p> <p>18 why the Department of Justice said that?</p> <p>19 A. Yes.</p> <p>20 Q. Okay. What is your</p> <p>21 understanding?</p> <p>22 A. That the Department of Justice</p> <p>23 felt like we were shipping a large quantity to --</p> <p>24 of hydrocodone combination products to customers</p>	<p style="text-align: right;">Page 24</p> <p>1 Justice they were wrong. Correct?</p> <p>2 MS. McCLURE: Objection to form.</p> <p>3 THE WITNESS: I don't know.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. Sitting here today, you're not</p> <p>6 aware of anyone responding to the Department of</p> <p>7 Justice in connection with this and saying the</p> <p>8 sales figures you're providing in your letter are</p> <p>9 incorrect.</p> <p>10 Would you agree with that?</p> <p>11 MS. McCLURE: Objection to form.</p> <p>12 THE WITNESS: Again, I don't know</p> <p>13 what was said.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. What was your title at this time?</p> <p>16 A. 2007, I would have -- I believe I</p> <p>17 was director of regulatory affairs.</p> <p>18 Q. Were the policies and procedures</p> <p>19 at the Orlando facility consistent with the</p> <p>20 company's policies around the country?</p> <p>21 MS. McCLURE: Objection to form.</p> <p>22 THE WITNESS: Yes, they were.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. So with respect to diversion</p>
<p style="text-align: right;">Page 23</p> <p>1 in Florida, in their opinion.</p> <p>2 Q. Were you in fact shipping the</p> <p>3 quantities that they said you were shipping?</p> <p>4 A. I can't verify that to the</p> <p>5 number.</p> <p>6 Q. Do you recall ever --</p> <p>7 A. I'm sure -- go ahead.</p> <p>8 Q. Do you recall ever disputing</p> <p>9 that the numbers that they were providing were</p> <p>10 incorrect?</p> <p>11 MS. McCLURE: Objection to form.</p> <p>12 THE WITNESS: I don't recall that</p> <p>13 we disputed it, no.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. So to your recollection, you</p> <p>16 never told the Department of Justice their</p> <p>17 numbers were wrong. Agreed?</p> <p>18 MS. McCLURE: Objection to form.</p> <p>19 THE WITNESS: I wasn't involved</p> <p>20 in the discussions with the Department of</p> <p>21 Justice.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. Okay. But to your knowledge, no</p> <p>24 one at AmerisourceBergen told the Department of</p>	<p style="text-align: right;">Page 25</p> <p>1 control, there was nothing different going on at</p> <p>2 the Orlando facility than there was at any other</p> <p>3 facility. Correct?</p> <p>4 MS. McCLURE: Objection to form.</p> <p>5 THE WITNESS: Not that I know of.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Do you know why you said earlier</p> <p>8 that the Department of Justice was concerned</p> <p>9 about the volume of these products, these</p> <p>10 hydrocodone combination products, that were being</p> <p>11 sold to customers? Agreed?</p> <p>12 MS. McCLURE: Objection to form.</p> <p>13 THE WITNESS: I agree that</p> <p>14 they -- I would assume they were</p> <p>15 concerned or they wouldn't have suspended</p> <p>16 the registration.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Why were they concerned about</p> <p>19 these volumes?</p> <p>20 MS. McCLURE: Objection to form.</p> <p>21 THE WITNESS: I don't know.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. You have no idea why this was a</p> <p>24 concern?</p>

Page 26	Page 28
<p>1 MS. McCLURE: Same objection.</p> <p>2 THE WITNESS: I didn't have any</p> <p>3 conversations with DEA about it, so I</p> <p>4 don't know how they formed that opinion.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Well, let's go to the second page</p> <p>7 here.</p> <p>8 Again, there's numbered</p> <p>9 paragraphs. There's a paragraph number 5 at the</p> <p>10 bottom there.</p> <p>11 A. Okay.</p> <p>12 Q. I'm going to read it to you, and</p> <p>13 tell me if I read it correctly.</p> <p>14 It says, "On August 10, 2005, DEA</p> <p>15 personnel met with Steve Mays, Respondent's</p> <p>16 Director of Regulatory Affairs, to inform him</p> <p>17 about the common characteristics of pharmacies</p> <p>18 that divert large amounts of controlled</p> <p>19 substances by filling invalid prescriptions</p> <p>20 obtained by customers using the Internet."</p> <p>21 Do you see that?</p> <p>22 A. Yes, I do.</p> <p>23 Q. Did I read that correctly?</p> <p>24 A. Yes, you did.</p>	<p>1 with the DEA, correct --</p> <p>2 A. Yes, I do.</p> <p>3 Q. -- in 2005?</p> <p>4 MS. McCLURE: Objection, asked</p> <p>5 and answered.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Who was present at this meeting?</p> <p>8 MS. McCLURE: Objection, asked</p> <p>9 and answered.</p> <p>10 THE WITNESS: Myself and Mike</p> <p>11 Mates (ph) from DEA. And then there was</p> <p>12 an attorney there, counsel, that I don't</p> <p>13 recall his name.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. Attorney for the Department of</p> <p>16 Justice?</p> <p>17 A. Yes. Or for DEA.</p> <p>18 Q. Okay. Was there anyone else from</p> <p>19 AmerisourceBergen who was present at this</p> <p>20 meeting?</p> <p>21 MS. McCLURE: Objection, asked</p> <p>22 and answered.</p> <p>23 THE WITNESS: No, there wasn't.</p> <p>24 BY MR. PIFKO:</p>
<p style="text-align: center;">Page 27</p> <p>1 Q. Do you recall having a meeting</p> <p>2 with DEA personnel on August 10, 2005?</p> <p>3 MS. McCLURE: Objection, asked</p> <p>4 and answered.</p> <p>5 THE WITNESS: I don't recall if</p> <p>6 that was the exact date, but I do recall</p> <p>7 the meeting, yes.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Does this refresh your</p> <p>10 recollection about what your title was on or</p> <p>11 around this time?</p> <p>12 A. Yes.</p> <p>13 Q. Okay. So when it says here that</p> <p>14 you were director of regulatory affairs, is that</p> <p>15 correct?</p> <p>16 A. That's correct.</p> <p>17 Q. Was that your title on or around</p> <p>18 the time that this order to show cause was</p> <p>19 issued?</p> <p>20 MS. McCLURE: Objection, asked</p> <p>21 and answered.</p> <p>22 THE WITNESS: I think so, yes.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. So you recall having this meeting</p>	<p style="text-align: center;">Page 29</p> <p>1 Q. Do you agree with the</p> <p>2 characterization in this letter that at that</p> <p>3 meeting they informed you about the common</p> <p>4 characteristics of pharmacies that divert large</p> <p>5 amounts of controlled substances by filling</p> <p>6 invalid prescriptions obtained by customers using</p> <p>7 the internet?</p> <p>8 A. Yes.</p> <p>9 Q. It says, going on to page 3, "DEA</p> <p>10 personnel reminded Respondent that under 21</p> <p>11 U.S.C. Sections 823(b)(1) and (e)(1), Respondent</p> <p>12 was responsible to prevent the diversion of</p> <p>13 controlled substances."</p> <p>14 Do you see that?</p> <p>15 A. I see that, yes.</p> <p>16 Q. Did I read that correctly?</p> <p>17 A. Yes, you did.</p> <p>18 Q. Do you recall the DEA informing</p> <p>19 you during that meeting that AmerisourceBergen</p> <p>20 was responsible for preventing diversion of</p> <p>21 controlled substances?</p> <p>22 MS. McCLURE: Objection to form.</p> <p>23 THE WITNESS: I don't recall that</p> <p>24 specifically.</p>

1 BY MR. PIFKO: 2 Q. How about generally? 3 MS. McCLURE: Same. 4 THE WITNESS: Same. 5 BY MR. PIFKO: 6 Q. Do you recall during that meeting 7 the DEA discussing AmerisourceBergen's 8 responsibilities under the Controlled Substances 9 Act? 10 MS. McCLURE: Objection to form. 11 THE WITNESS: Not specifically. 12 BY MR. PIFKO: 13 Q. How about generally, do you 14 remember -- 15 A. That was 12 years ago. 16 Q. Okay. How about generally, do 17 you remember them discussing any expectations 18 about what AmerisourceBergen was supposed to do 19 with respect to complying with the Controlled 20 Substances Act? 21 MS. McCLURE: Objection to form. 22 THE WITNESS: Not specifically. 23 BY MR. PIFKO: 24 Q. How about generally?	Page 30 1 BY MR. PIFKO: 2 Q. Who would you have told if you 3 told someone? 4 MS. McCLURE: Objection to form, 5 calls for speculation. 6 THE WITNESS: I would have to 7 speculate. I don't know. I couldn't 8 tell you for sure. Again, that was 12 9 years ago. 10 BY MR. PIFKO: 11 Q. Okay. Next sentence here, 12 "Notwithstanding the information provided to 13 Respondent, after the August 10, 2005 meeting, 14 Respondent sold over 5.2 million dosage units of 15 hydrocodone to pharmacies that bore the 16 characteristics that DEA described in the August 17 10, 2005 meeting." 18 Do you see that? 19 A. Yes, I do. 20 Q. Did I read that correctly? 21 A. I believe you did. 22 Q. Do you agree with that statement? 23 MS. McCLURE: Objection to form. 24 THE WITNESS: I can't verify the
Page 31 1 MS. McCLURE: Same objection. 2 THE WITNESS: Not -- not 3 generally. 4 BY MR. PIFKO: 5 Q. So you don't have any 6 recollection of whether you discussed the 7 Controlled Substances Act at that meeting? 8 MS. McCLURE: Objection, asked 9 and answered. 10 THE WITNESS: Not specifically. 11 BY MR. PIFKO: 12 Q. When you left that meeting, you 13 reported back to Chris Zimmerman. Correct? 14 MS. McCLURE: Objection, asked 15 and answered. 16 THE WITNESS: I don't recall that 17 I did. 18 BY MR. PIFKO: 19 Q. Did you tell anybody about that 20 meeting? 21 MS. McCLURE: Same objection. 22 THE WITNESS: Not -- I don't 23 recall specifically. I'm sure I did, but 24 I don't recall specifically.	Page 33 1 quantities. 2 BY MR. PIFKO: 3 Q. Other than verifying the 4 quantities, do you agree with that statement? 5 MS. McCLURE: Same objection. 6 THE WITNESS: I can't really 7 agree with it because I don't -- I don't 8 know. I don't recall. 9 BY MR. PIFKO: 10 Q. You don't know either way? 11 A. No. 12 Q. Do you have any reason to dispute 13 that AmerisourceBergen sold over 5.2 million 14 dosage units of hydrocodone products to 15 pharmacies that bore the characteristics 16 discussed at this August 10, 2005 meeting? 17 MS. McCLURE: Objection to form. 18 THE WITNESS: I don't have any 19 specific reason to dispute it, no. 20 BY MR. PIFKO: 21 Q. Do you remember the DEA 22 discussing specific characteristics of 23 hydrocodone products during the August 10, 2005 24 meeting?

Page 34	Page 36
<p>1 MS. McCLURE: Objection to form, 2 asked and answered.</p> <p>3 THE WITNESS: Characteristics of 4 hydrocodone products? Not that I recall.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. How about do you recall DEA 7 describing certain characteristics of sales to 8 certain types of pharmacies?</p> <p>9 MS. McCLURE: Objection to form.</p> <p>10 THE WITNESS: I recall that, yes.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. What specifically do you recall 13 about that?</p> <p>14 A. We discussed characteristics of 15 internet pharmacy and what to look for.</p> <p>16 Q. What specifically were you 17 supposed to look for with respect to internet 18 pharmacies?</p> <p>19 MS. McCLURE: Objection to form.</p> <p>20 THE WITNESS: I don't recall 21 everything. A few things. I can tell 22 you what I do remember.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. Yeah, that's what I'm asking.</p>	<p>1 Q. Do you recall writing anything 2 down to change AmerisourceBergen's procedures 3 with respect to the due diligence it may perform 4 with respect to customers after you had this 5 meeting?</p> <p>6 MS. McCLURE: Objection to form.</p> <p>7 THE WITNESS: I don't recall 8 writing things down.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Do you recall changing any 11 policies or procedures in order to look for the 12 criteria that the Department of Justice 13 identified to you during this meeting?</p> <p>14 MS. McCLURE: Objection to form, 15 assumes facts not in evidence, 16 foundation.</p> <p>17 THE WITNESS: I don't recall 18 specifically.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. How about generally?</p> <p>21 MS. McCLURE: Same.</p> <p>22 THE WITNESS: Generally, I know 23 we made some changes.</p> <p>24 BY MR. PIFKO:</p>
Page 35	Page 37
<p>1 A. Okay. I'm trying to recall. 2 To look for like FedEx boxes or 3 UPS boxes piled up in the pharmacy that would 4 indicate they're shipping drugs other than just 5 filling them at the store. Other than that, I 6 can't remember the specifics.</p> <p>7 Q. When you came back to this 8 meeting, did you instruct anyone at 9 AmerisourceBergen to look for those type of 10 characteristics?</p> <p>11 MS. McCLURE: Objection to form.</p> <p>12 THE WITNESS: I don't recall 13 specifically.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. How about generally?</p> <p>16 MS. McCLURE: Same.</p> <p>17 THE WITNESS: I'm sure I did, I 18 just don't recall.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. Who would you have told?</p> <p>21 MS. McCLURE: Objection to form.</p> <p>22 THE WITNESS: Don't recall 23 specifically.</p> <p>24 BY MR. PIFKO:</p>	<p>1 Q. What changes did you make? 2 A. In -- we started conducting due 3 diligence of customers --</p> <p>4 Q. What was --</p> <p>5 A. -- that had the parameters of our 6 program --</p> <p>7 Q. Any other things --</p> <p>8 A. -- on the reports.</p> <p>9 Q. Anything else that you changed?</p> <p>10 A. I can't recall specifically.</p> <p>11 Q. What was the nature of the due 12 diligence that you started performing at that 13 time?</p> <p>14 A. We started using a questionnaire 15 in the due diligence.</p> <p>16 Q. Was there a name for the 17 questionnaire?</p> <p>18 A. A name of it? Can't recall 19 specifically what the name was.</p> <p>20 Q. Who was supposed to fill out this 21 questionnaire?</p> <p>22 MS. McCLURE: Objection to form.</p> <p>23 THE WITNESS: The 24 AmerisourceBergen sales representative,</p>
Golkow Litigation Services	

<p style="text-align: right;">Page 38</p> <p>1 along with the customer.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. And then what would you do with</p> <p>4 that questionnaire?</p> <p>5 MS. McCLURE: Objection to form.</p> <p>6 THE WITNESS: Well, we would</p> <p>7 review that to see if they answered the</p> <p>8 questions adequately to -- so we could</p> <p>9 ensure that they weren't engaged in that</p> <p>10 type of activity.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Did you do anything else?</p> <p>13 A. Not specifically. I don't know</p> <p>14 what you're asking.</p> <p>15 Q. What was the nature of your</p> <p>16 review to determine if the customer adequately</p> <p>17 provided information?</p> <p>18 A. I'm not sure what you're asking.</p> <p>19 Q. You said you would review the</p> <p>20 question to see if the -- they were adequately</p> <p>21 filled out so you could ensure that they weren't</p> <p>22 engaged in that type of activity.</p> <p>23 A. Right.</p> <p>24 Q. So I'm asking, what was the</p>	<p style="text-align: right;">Page 40</p> <p>1 and answered.</p> <p>2 THE WITNESS: I don't recall</p> <p>3 specifically, but I believe that was part</p> <p>4 of the questionnaire.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Let's go back to Exhibit 1 here.</p> <p>7 On the third page of the exhibit,</p> <p>8 tell me when you're there.</p> <p>9 A. Oh. I thought that's where we</p> <p>10 were.</p> <p>11 Q. Yeah, we were.</p> <p>12 A. Okay.</p> <p>13 Q. It's got a bunch of -- well,</p> <p>14 remember we just read a sentence in the top of</p> <p>15 the first paragraph.</p> <p>16 A. Uh-huh.</p> <p>17 Q. Starting where we left off, it</p> <p>18 says, "Respondent continued to sell controlled</p> <p>19 substances to Grand, Discount Mail Meds and" Med</p> <p>20 Assistant "even though Respondent knew, or should</p> <p>21 have known, that these pharmacies were diverting</p> <p>22 controlled substances into other than legitimate</p> <p>23 medical, scientific and industrial channels."</p> <p>24 Do you see that?</p>
<p style="text-align: right;">Page 39</p> <p>1 nature of your review to conduct that analysis?</p> <p>2 MS. McCLURE: Form.</p> <p>3 THE WITNESS: We would verify as</p> <p>4 much of the information as they gave us.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. How would you verify it?</p> <p>7 A. I can't remember specifically.</p> <p>8 You know, if they gave us a website or something</p> <p>9 like that, we would verify that website, to make</p> <p>10 sure that they weren't filling prescriptions</p> <p>11 based on the questionnaire.</p> <p>12 Q. Did the questionnaire include any</p> <p>13 photographs?</p> <p>14 MS. McCLURE: Objection, form.</p> <p>15 THE WITNESS: I can't remember in</p> <p>16 the beginning if we required photographs,</p> <p>17 but I know at some point we required</p> <p>18 the -- whoever went on site, typically it</p> <p>19 was a salesperson, to take photographs</p> <p>20 inside and outside of the building.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. Did you ask people to look for</p> <p>23 FedEx packages?</p> <p>24 MS. McCLURE: Objection, asked</p>	<p style="text-align: right;">Page 41</p> <p>1 A. Yes, I see that.</p> <p>2 Q. Did I read that correctly?</p> <p>3 A. Yes, you did.</p> <p>4 Q. If you go back to page 2,</p> <p>5 paragraph 3, it talks about how AmerisourceBergen</p> <p>6 distributed approximately a million dosage units</p> <p>7 of hydrocodone products to Grand Pharmacy.</p> <p>8 Do you see that?</p> <p>9 MS. McCLURE: Objection to form.</p> <p>10 THE WITNESS: I do.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Did I read that correct -- did I</p> <p>13 summarize that correctly?</p> <p>14 A. I believe you did.</p> <p>15 Q. Okay. And then in paragraph 4,</p> <p>16 it talks about supplying hydrocodone products to</p> <p>17 a number of other pharmacies.</p> <p>18 Do you see that?</p> <p>19 A. Yes, I do.</p> <p>20 Q. And then it says in paragraph 4</p> <p>21 that the distribution of those was under</p> <p>22 circumstances that should have alerted</p> <p>23 AmerisourceBergen that the pharmacies were</p> <p>24 diverting hydrocodone.</p>

Page 42	Page 44
<p>1 Do you see that?</p> <p>2 A. You said paragraph 4?</p> <p>3 Q. Yeah. The last sentence in the</p> <p>4 bottom of that first paragraph there.</p> <p>5 A. Okay. I see it.</p> <p>6 Q. Did I read that correctly?</p> <p>7 A. Yes, sir.</p> <p>8 Q. Okay. Do you believe that the</p> <p>9 policies and procedures that you implemented</p> <p>10 after this August 2005 meeting were sufficient to</p> <p>11 detect diversion?</p> <p>12 MS. McCLURE: Objection, form.</p> <p>13 THE WITNESS: I believe that the</p> <p>14 actions that we took enabled us to</p> <p>15 identify internet pharmacies. And I</p> <p>16 think we ceased distributing to some of</p> <p>17 these. I can't tell you exactly which</p> <p>18 ones, but I believe we cut those off.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. After you received this letter?</p> <p>21 A. No. I think some of these were</p> <p>22 cut off before this action was taken. I can't --</p> <p>23 I don't remember specifically which ones, but I</p> <p>24 do recall that when this happened, some of these</p>	<p>1 have known that they were diverting them to</p> <p>2 illegitimate channels, you still feel like the</p> <p>3 company was doing enough, as the director of</p> <p>4 regulatory affairs?</p> <p>5 MS. McCLURE: Objection, form.</p> <p>6 THE WITNESS: I felt like we were</p> <p>7 doing the best we could as a distributor</p> <p>8 to comply with the regulations. And we</p> <p>9 took steps to improve our due diligence</p> <p>10 and our monitoring of our customers.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Do you believe you took adequate</p> <p>13 steps to improve your due diligence and monitor</p> <p>14 customers?</p> <p>15 MS. McCLURE: Objection, form.</p> <p>16 THE WITNESS: Yes.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Going to page 3 here, it says, in</p> <p>19 the middle of the second paragraph -- tell me</p> <p>20 when you're there -- "it is my preliminary</p> <p>21 conclusion that Respondent's continued</p> <p>22 registration while these proceedings are pending</p> <p>23 would constitute an imminent danger to the public</p> <p>24 health and safety because of the substantial</p>
<p>Page 43</p> <p>1 customers that were mentioned, we had cut off</p> <p>2 before the suspension.</p> <p>3 Q. Did receiving this letter cause</p> <p>4 AmerisourceBergen to be concerned that it wasn't</p> <p>5 doing enough to comply with diversion control</p> <p>6 laws and regulations?</p> <p>7 MS. McCLURE: Objection to form.</p> <p>8 THE WITNESS: I couldn't tell you</p> <p>9 what the company thought.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. How about you? You were</p> <p>12 regulatory affairs manager.</p> <p>13 A. Director.</p> <p>14 Q. Director.</p> <p>15 A. Uh-huh.</p> <p>16 Q. Did you feel like the company was</p> <p>17 doing enough to prevent diversion when you</p> <p>18 received this order to show cause?</p> <p>19 MS. McCLURE: Objection, form.</p> <p>20 THE WITNESS: Yes, I did.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. So even though the Department of</p> <p>23 Justice said that you were distributing</p> <p>24 substances to customers when you knew or should</p>	<p>Page 45</p> <p>1 likelihood that Respondent will continue to</p> <p>2 supply pharmacies that divert large quantities of</p> <p>3 controlled substances."</p> <p>4 Did I read that correctly?</p> <p>5 A. Yes, you did.</p> <p>6 Q. Upon receiving that, did that</p> <p>7 give you, as the director of compliance and</p> <p>8 regulatory issues, concern about whether the</p> <p>9 company's practices were sufficient?</p> <p>10 MS. McCLURE: Objection to form.</p> <p>11 THE WITNESS: No.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. Did you think the Department of</p> <p>14 Justice's conclusions were wrong?</p> <p>15 A. I think so, yeah. They weren't</p> <p>16 completely accurate, in my opinion.</p> <p>17 Q. Why do you say that they weren't</p> <p>18 completely accurate?</p> <p>19 A. I can't really say. I just don't</p> <p>20 think they were completely accurate. I felt like</p> <p>21 we were doing the best we could to monitor the</p> <p>22 distribution of these drugs.</p> <p>23 Q. Do you have any factual basis to</p> <p>24 challenge that Department of Justice's conclusion</p>

1 there? 2 MS. McCLURE: Objection to form, 3 asked and answered. 4 THE WITNESS: Not today I don't, 5 no. 6 BY MR. PIFKO: 7 Q. Do you know what happened after 8 you received -- the company received this letter? 9 MS. McCLURE: Form. 10 THE WITNESS: What do you mean, 11 what happened? 12 BY MR. PIFKO: 13 Q. The Orlando facility did get its 14 registration suspended. Correct? 15 A. Yes, that's correct. 16 Q. And you had to halt shipments of 17 product for some time period from that facility. 18 Correct? 19 MS. McCLURE: Objection, form. 20 THE WITNESS: Ask the question 21 again, please, I'm sorry. 22 BY MR. PIFKO: 23 Q. You had to halt shipments of 24 product from that facility for some period of	Page 46 1 BY MR. PIFKO: 2 Q. Are you aware of any other 3 actions where the DEA was investigating the 4 company for potential violations of diversion 5 control laws? 6 A. I -- actions -- I mean, I can't 7 recall specifics. 8 Q. How about generally? 9 A. There's always investigations. 10 They inspect our facilities frequently, and there 11 could -- there's always -- I shouldn't say 12 always, but often there's minor violations that 13 are part of their investigation, part of the 14 Controlled Substances Act and the regulations. 15 Q. Do you recall any criminal 16 investigations that were occurring with respect 17 to AmerisourceBergen's diversion control 18 practices? 19 A. I assume if the New Jersey case 20 is considered a criminal action, yes. 21 Q. Okay. What do you know about the 22 New Jersey case? 23 MS. McCLURE: Objection to form. 24 THE WITNESS: I just know that
1 time after that. Correct? 2 MS. McCLURE: Objection, form. 3 THE WITNESS: We had to halt 4 shipments of controlled substances from 5 the facility. 6 BY MR. PIFKO: 7 Q. Do you know how long that was in 8 place, where you weren't allowed to ship 9 controlled substances from that facility? 10 A. I couldn't tell you exactly, but 11 it was about three months. 12 Q. Some years later, the Houston 13 facility also almost lost its registration. 14 Correct? 15 MS. McCLURE: Objection to form. 16 THE WITNESS: I don't know what 17 you're talking about. 18 BY MR. PIFKO: 19 Q. You don't have any recollection 20 of the DEA almost suspending the registration of 21 the Houston facility? 22 MS. McCLURE: Objection to form. 23 THE WITNESS: I have no 24 knowledge. No knowledge of that.	Page 47 1 it's a -- that it was a criminal case 2 that I think began in 2012, I believe. 3 BY MR. PIFKO: 4 Q. Did it concern the company's 5 diversion control practices? 6 A. I believe so. 7 Q. When did you first learn about 8 that? 9 A. I learned about that because I 10 was the person they called to ask where to send 11 the initial subpoena. So it was sometime in 12 2012, I believe. 13 Q. So the Department -- 14 A. I'm sorry. When I say "they," 15 New York US -- I don't know if it was US Attorney 16 or New York AG. I can't remember. 17 Q. Okay. So someone from a 18 government enforcement agency contacted you and 19 said they were going to send a subpoena to the 20 company and asked where to send it? 21 A. That's what I recall, yes. 22 Q. Okay. What did you do when you 23 received that inquiry? 24 MS. McCLURE: Objection to form.

	Page 50	Page 52
1	THE WITNESS: I don't remember	[REDACTED]
2	exactly. I'm sure I gave it to legal.	[REDACTED]
3	BY MR. PIFKO:	[REDACTED]
4	Q. Okay. Did you discuss that with	[REDACTED]
5	Mr. Chris Zimmerman?	[REDACTED]
6	A. I'm sure I would have. He's my	[REDACTED]
7	boss, yes.	[REDACTED]
8	Q. And he had responsibility for	[REDACTED]
9	diversion control issues as well. Correct?	[REDACTED]
10	MS. McCLURE: Objection to form.	[REDACTED]
11	THE WITNESS: He's our department	[REDACTED]
12	head, so he's got high level	[REDACTED]
13	responsibility for all that.	[REDACTED]
14	BY MR. PIFKO:	[REDACTED]
15	Q. Did you ever speak to anyone at	[REDACTED]
16	the DEA or the US Attorney's Office in connection	[REDACTED]
17	with that investigation?	[REDACTED]
18	A. No, I don't believe so.	[REDACTED]
19	Q. Did you compile documents to	[REDACTED]
20	respond to the subpoena?	[REDACTED]
21	MS. McCLURE: Objection to form.	[REDACTED]
22	THE WITNESS: Personally, I don't	[REDACTED]
23	think so, no.	[REDACTED]
24	BY MR. PIFKO:	[REDACTED]
	Page 51	Page 53
1	Q. Did you ever personally receive	[REDACTED]
2	the subpoena that the call was about?	[REDACTED]
3	MS. McCLURE: Objection to form.	[REDACTED]
4	THE WITNESS: I can't remember if	[REDACTED]
5	they sent it -- I can't remember if it	[REDACTED]
6	came directly to me or not.	[REDACTED]
7	BY MR. PIFKO:	[REDACTED]
8	Q. Do you recall discussing the	[REDACTED]
9	investigation with any other members of the	[REDACTED]
10	diversion control team?	[REDACTED]
11	A. Not specifically.	[REDACTED]
12	Q. How about generally?	[REDACTED]
13	A. Generally, I'm sure, yes.	[REDACTED]
14	Q. Do you know who Mr. Tomkiewicz	[REDACTED]
15	is?	[REDACTED]
16	A. Yes.	[REDACTED]
17	Q. Did you discuss the Department of	[REDACTED]
18	Justice investigation with Mr. Tomkiewicz?	[REDACTED]
19	A. No, not specifically. I don't	[REDACTED]
20	think he was with us at the time.	[REDACTED]

Page 54	Page 56
<p>1 BY MR. PIFKO:</p> <p>2 Q. Did you make any changes to the 3 company's practices after learning about that 4 investigation?</p> <p>5 MS. McCLURE: Objection to form.</p> <p>6 THE WITNESS: I don't recall 7 making any changes.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Were you concerned at the time 10 that there were criminal investigations of 11 AmerisourceBergen that were occurring?</p> <p>12 MS. McCLURE: Objection to form.</p> <p>13 THE WITNESS: Oh, yes, I was 14 concerned. Yes.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. Why were you concerned?</p> <p>17 A. Because we were being 18 investigated.</p> <p>19 Q. Why did being investigated give 20 you cause for concern?</p> <p>21 A. That's always a concern. If 22 you're being investigated, that's a concern.</p> <p>23 Q. Do you know what the ultimate 24 outcome of that investigation was?</p>	<p>1 MS. McCLURE: Objection, asked 2 and answered.</p> <p>3 THE WITNESS: Would that be prior 4 to the suspension?</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Yes.</p> <p>7 A. Is that what you're asking?</p> <p>8 Q. Yes.</p> <p>9 A. As I recall, it would be the same 10 as any of the other facilities.</p> <p>11 Q. Okay. So at the time this letter 12 was sent, AmerisourceBergen's diversion control 13 systems were the same at all of its distribution 14 centers. Correct?</p> <p>15 MS. McCLURE: Objection to form.</p> <p>16 THE WITNESS: That's what I 17 recall, yes.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. So anything occurring at this 20 Orlando facility could be occurring at any other 21 distribution center. Correct?</p> <p>22 MS. McCLURE: Objection, form.</p> <p>23 THE WITNESS: I disagree.</p> <p>24 BY MR. PIFKO:</p>
<p>1 A. No, I don't.</p> <p>2 Q. Okay.</p> <p>3 A. My understanding, it's still 4 ongoing.</p> <p>5 MR. PIFKO: Let's take a short 6 break.</p> <p>7 THE VIDEOGRAPHER: Going off the 8 record at 11:50 a.m.</p> <p>9 - - -</p> <p>10 (A recess was taken from 11 11:50 a.m. to 12:07 p.m.)</p> <p>12 - - -</p> <p>13 THE VIDEOGRAPHER: Back on the 14 record at 12:07 p.m.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. I want to bring your attention 17 back to Exhibit 1.</p> <p>18 A. Okay.</p> <p>19 Q. All right. So I just want to 20 confirm, as we discussed before we went on the 21 break, there was nothing different about the 22 procedures at the Orlando facility as opposed to 23 any other facility, any other distribution 24 facility ran by AmerisourceBergen. Correct?</p>	<p>1 Q. What do you disagree?</p> <p>2 A. Because they're a different 3 customer base, different region of the country.</p> <p>4 Q. But with respect to 5 AmerisourceBergen's procedures, the same things 6 that are occurring at this facility are the same 7 thing that are occurring at other facilities.</p> <p>8 Correct?</p> <p>9 MS. McCLURE: Objection to form.</p> <p>10 THE WITNESS: As far as our 11 procedures and how -- our policies and 12 procedures, yes, they're -- they would be 13 the same for all of the distribution 14 centers.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. Okay. Did AmerisourceBergen 17 employ any sort of different system to monitor 18 internet pharmacies as opposed to retail 19 pharmacies or chain pharmacies?</p> <p>20 MS. McCLURE: Objection, form.</p> <p>21 THE WITNESS: No. As far as a 22 system itself, no.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. So AmerisourceBergen's system</p>
Page 55	Page 57

Page 58	Page 60
<p>1 used to monitor internet pharmacies was the same 2 system that it used to monitor retail and chain 3 pharmacies. Correct?</p> <p>4 MS. McCLURE: Objection, form.</p> <p>5 THE WITNESS: Well, we weren't 6 specifically monitoring internet 7 pharmacies. We were monitoring our 8 customers, our pharmacy customers.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. And that system that was used was 11 the same for all customers, regardless of the 12 type of customers. Correct?</p> <p>13 MS. McCLURE: Objection to form, 14 asked and answered.</p> <p>15 THE WITNESS: As I recall, yes.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Let's go to page 2 of Exhibit 1.</p> <p>18 A. Okay.</p> <p>19 Q. So looking at paragraph 4, it 20 says, the bottom of paragraph 4, "Respondent 21 distributed hydrocodone under the following 22 circumstances that should have alerted Respondent 23 that the pharmacies were diverting hydrocodone." 24 Do you see that?</p>	<p>1 MS. McCLURE: Objection.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. -- at that time?</p> <p>4 MS. McCLURE: Asked and answered.</p> <p>5 THE WITNESS: As I recall, it was 6 a system that generated a report that 7 indicated any orders that were above 8 certain parameters looking back over that 9 customer's average purchases. And they 10 would be flagged on that report if they 11 exceeded that average or that parameter.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. So you agree here that the DEA is 14 saying in this letter that AmerisourceBergen 15 nevertheless distributed hydrocodone to 16 pharmacies even though the amounts exceeded what 17 an average pharmacy would order for legitimate 18 needs.</p> <p>19 Do you see that?</p> <p>20 MS. McCLURE: Objection, form.</p> <p>21 THE WITNESS: You're on the 22 subparagraph A?</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. Yes.</p>
Page 59	Page 61
<p>1 A. Yes, I do.</p> <p>2 Q. Did I read that correctly?</p> <p>3 A. Yes, you did.</p> <p>4 Q. Then it's got subparts A through 5 D.</p> <p>6 Do you see those?</p> <p>7 A. Yes, I do.</p> <p>8 Q. Part A says, "Respondent 9 distributed hydrocodone to each of the named 10 pharmacies, and others, in amounts that far 11 exceeded what an average pharmacy orders to meet 12 the legitimate needs of its customers."</p> <p>13 Do you see that?</p> <p>14 A. Yes, I do.</p> <p>15 Q. Did I read that correctly?</p> <p>16 A. Yes, you did.</p> <p>17 Q. "Respondent knew that orders of 18 an unusual size were 'suspicious' as that term is 19 used in 21 C.F.R. section 1301.74(b)."</p> <p>20 Did I read that correctly?</p> <p>21 A. Yes, you did.</p> <p>22 Q. What was AmerisourceBergen's 23 system that was in place to monitor the amounts 24 that its customers ordered --</p>	<p>1 A. I agree that that's what DEA is 2 saying, yes.</p> <p>3 Q. So did AmerisourceBergen at this 4 time not have a way of monitoring what a 5 customer's volume was with -- as compared to what 6 an average pharmacy would need to meet legitimate 7 needs of its customers?</p> <p>8 MS. McCLURE: Objection, form.</p> <p>9 THE WITNESS: I don't recall the 10 specific algorithms of that program.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. You believe there was a program 13 that had algorithms?</p> <p>14 A. I'm sorry?</p> <p>15 Q. You believe there was a program 16 that had some algorithm?</p> <p>17 A. I don't know if algorithm is a 18 correct word, but it had a formula built into the 19 system, a certain percentage. And it basically 20 looked at that customer's purchases over, I 21 believe it was -- I believe it was a rolling 22 three-month average. And if it exceeded that by 23 a certain amount, then it would be flagged on 24 this report as a possible excessive order.</p>

Page 62	Page 64
<p>1 Q. But according to DEA, you failed 2 to alert DEA and you failed to prevent orders of 3 unusual size from being shipped to customers. 4 Correct?</p> <p>5 MS. McCLURE: Objection to form.</p> <p>6 THE WITNESS: Can you repeat that 7 again? I'm sorry.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Yes. So in A here it's saying 10 that you nevertheless shipped orders beyond what 11 an average pharmacy needed?</p> <p>12 MS. McCLURE: Objection, form.</p> <p>13 THE WITNESS: I don't know what 14 an average pharmacy needed.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. Okay.</p> <p>17 A. So...</p> <p>18 Q. So at the time AmerisourceBergen 19 had no way of evaluating what an average pharmacy 20 needed; is that correct?</p> <p>21 MS. McCLURE: Objection, form.</p> <p>22 THE WITNESS: We only had the 23 ability to know what our customers were 24 purchasing.</p>	<p>1 MS. McCLURE: Objection, asked 2 and answered.</p> <p>3 THE WITNESS: I see that in 4 general, yes.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. And if you go on the first page 7 here, it says that, in paragraph 1, "Respondent 8 distributed over 3.8 million dosage units of 9 combination hydrocodone products to customers 10 that it knew or should have known were diverting 11 the hydrocodone into other than legitimate 12 medical, scientific and industrial channels."</p> <p>13 Do you see that?</p> <p>14 MS. McCLURE: Objection, form.</p> <p>15 THE WITNESS: I see that.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. And so my question to you is, 18 there's a failure of AmerisourceBergen to catch 19 this volumes that the Department of Justice 20 identified. Correct?</p> <p>21 MS. McCLURE: Objection, form.</p> <p>22 THE WITNESS: In their opinion, 23 yes.</p> <p>24 BY MR. PIFKO:</p>
Page 63	Page 65
<p>1 BY MR. PIFKO:</p> <p>2 Q. Did you take any steps to know 3 what the average pharmacy within your own 4 customers would need to fill legitimate needs of 5 its customers?</p> <p>6 MS. McCLURE: Objection, form.</p> <p>7 THE WITNESS: I don't recall.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Would you agree that there was a 10 failure of AmerisourceBergen's system that led to 11 the receipt of this order to show cause?</p> <p>12 MS. McCLURE: Objection, form.</p> <p>13 THE WITNESS: No, I don't agree 14 that there was a failure to our system.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. Going to page 3 here, the top 17 paragraph. We looked at this earlier.</p> <p>18 A. Uh-huh.</p> <p>19 Q. It said that AmerisourceBergen 20 shipped over 5.2 million dosage units of 21 hydrocodone to pharmacies that had certain 22 characteristics that were discussed in your 23 August 10, 2005 meeting.</p> <p>24 Do you see that?</p>	<p>1 Q. What I'm trying to understand is 2 where -- what occurred to result in that failure?</p> <p>3 MS. McCLURE: Objection to form.</p> <p>4 THE WITNESS: I didn't say there 5 was a failure.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Did you not know that those 8 volumes of hydrocodone products were being 9 shipped to AmerisourceBergen customers?</p> <p>10 A. I didn't know personally, no.</p> <p>11 Q. Was the company doing anything to 12 monitor the potentially significant volumes of 13 hydrocodone products that were being shipped to 14 its customers?</p> <p>15 MS. McCLURE: Objection, form.</p> <p>16 THE WITNESS: We had a suspicious 17 order monitoring program.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Okay. So did the system just not 20 catch these orders?</p> <p>21 MS. McCLURE: Objection, form.</p> <p>22 THE WITNESS: I couldn't tell you 23 that.</p> <p>24 BY MR. PIFKO:</p>

Page 66	Page 68
<p>1 Q. Do you know if the system caught 2 these orders and then they were simply released? 3 MS. McCLURE: Objection, form. 4 THE WITNESS: If these orders 5 were suspicious, they would have been on 6 that report and they would have been 7 reported to DEA as suspicious. 8 BY MR. PIFKO: 9 Q. The DEA here is saying these 10 orders are suspicious. 11 Do you agree? Let's look at page 12 2, paragraph 4a. 13 MS. McCLURE: Objection. 14 BY MR. PIFKO: 15 Q. "Respondent knew that orders of 16 an unusual size were 'suspicious' as that term is 17 used in 21 C.F.R. Section 1301.74(b)." 18 MS. McCLURE: What's the 19 question? 20 THE WITNESS: Yeah. 21 BY MR. PIFKO: 22 Q. My question to you was, the DEA 23 was saying these orders were suspicious. 24 Correct?</p>	<p>1 THE WITNESS: Again, I don't know 2 what an average pharmacy's purchases 3 were. 4 BY MR. PIFKO: 5 Q. Okay. So AmerisourceBergen had 6 no steps to monitor what an average pharmacy's 7 needs were at that time. 8 MS. McCLURE: Objection. 9 BY MR. PIFKO: 10 Q. Is that correct? 11 A. That's -- 12 MS. McCLURE: Objection, form, 13 asked and answered and misstates the 14 witness's prior testimony. 15 You may answer. 16 THE WITNESS: I disagree. We 17 have a suspicious order monitoring 18 program. 19 BY MR. PIFKO: 20 Q. Okay. But you just said, I don't 21 know what an average pharmacy would need. 22 A. That's correct. 23 Q. Did AmerisourceBergen have any 24 policies or procedures in place to evaluate what</p>
Page 67	Page 69
<p>1 MS. McCLURE: Objection. 2 Objection, form. 3 THE WITNESS: I don't see where 4 DEA says those orders were suspicious. 5 BY MR. PIFKO: 6 Q. Well, it's saying each of these 7 pharmacies and others where you distributed 8 hydrocodone products to them in amounts that far 9 exceeded what an average pharmacy orders to meet 10 the legitimate needs of its customers. 11 Do you see that? 12 A. Yes, I see that. 13 Q. Okay. And it's talking about 14 orders that AmerisourceBergen shipped to its 15 customers. Correct? 16 A. Yes, yes, that's correct. 17 Q. And then it says, you knew that 18 orders of an unusual size were suspicious. 19 Do you see that? 20 A. I see that. 21 Q. Did you not know that the orders 22 that exceeded what an average pharmacy would need 23 were suspicious? 24 MS. McCLURE: Objection to form.</p>	<p>1 an average pharmacy might need? 2 MS. McCLURE: Objection, form. 3 THE WITNESS: We have a 4 suspicious order monitoring program to 5 monitor our own customers. We don't 6 know -- we didn't know what an average 7 pharmacy purchased, what the quantities 8 were for an average pharmacy. 9 BY MR. PIFKO: 10 Q. So at that time, there was 11 nothing in AmerisourceBergen's system to evaluate 12 what an average pharmacy might need for its 13 legitimate needs for its customers. Correct? 14 MS. McCLURE: Objection, form. 15 THE WITNESS: Not other than our 16 own customers. That's the only data we 17 have or that we had at that time. 18 BY MR. PIFKO: 19 Q. But you were saying, under 20 AmerisourceBergen's systems in place at that 21 time, it only monitored the average of each 22 customer against its own orders at that time. 23 Correct? 24 MS. McCLURE: Objection, form.</p>

<p>1 THE WITNESS: That's what I 2 recall, yes. 3 BY MR. PIFKO: 4 Q. You weren't undertaking any 5 effort to compare a pharmacy's orders compared to 6 another pharmacy's orders at that time. Correct? 7 MS. McCLURE: Objection to form. 8 THE WITNESS: Not that I know of. 9 BY MR. PIFKO: 10 Q. Let's go to paragraph 4b. 11 A. Okay. 12 Q. It says, "Respondent distributed 13 hydrocodone to each of the named pharmacies, and 14 others, even though the pharmacies ordered small 15 amounts of other drug products relative to the 16 pharmacies' hydrocodone purchases from 17 Respondent." 18 Do you see that? 19 A. Yes, I do. 20 Q. "Respondent knew orders for large 21 amounts of hydrocodone in combination with small 22 amounts of other drug products deviated from the 23 normal pattern of orders placed by pharmacies." 24 Do you see that?</p>	<p>Page 70</p> <p>1 Q. Okay. Did you have any system in 2 place to monitor its purchasing of Schedule II or 3 III controlled substances as it compared to other 4 types of substances? 5 A. Not that I know of. 6 Q. Let's go to paragraph 4c. 7 It says, "Respondent distributed 8 hydrocodone to each of the named pharmacies, and 9 others, even though the pharmacies ordered 10 hydrocodone much more frequently than 11 Respondent's other pharmacy customers." 12 Do you see that? 13 A. Yes, I do. 14 Q. Did I read that correctly? 15 A. Yes, you did. 16 Q. It says, "Respondent knew that 17 orders of unusual frequency were 'suspicious' as 18 that term is used in 21 C.F.R. Section 19 1301.74(b)." 20 Did I read that correct? 21 A. That's correct. 22 Q. Did AmerisourceBergen have any 23 system in place at that time to evaluate the 24 frequency of orders of controlled substances</p>
<p>1 A. I see that. 2 Q. Did you know, as the head of 3 regulatory and compliance issues for diversion 4 control at that time, that an order for large 5 amounts of hydrocodone as compared to other drug 6 products was something that deviated from the 7 normal pattern of ordering for a pharmacy? 8 MS. McCLURE: Objection, form. 9 THE WITNESS: Repeat the 10 question, please? 11 BY MR. PIFKO: 12 Q. Did you know, as the head of 13 regulatory and compliance issues for diversion 14 control issues at that time, that an order for 15 large amounts of hydrocodone, as compared to 16 other drug products, was something that deviated 17 from the normal pattern of ordering for a 18 pharmacy? 19 MS. McCLURE: Objection to form. 20 THE WITNESS: We were -- we 21 monitored the purchases of that customer, 22 compared to their previous purchases, is 23 the way our system worked. 24 BY MR. PIFKO:</p>	<p>Page 71</p> <p>1 placed by its customers? 2 MS. McCLURE: Objection to form. 3 THE WITNESS: Not that I know of. 4 BY MR. PIFKO: 5 Q. You said something earlier 6 about -- that after the 2005 meeting with DEA 7 that's referenced in here -- 8 A. Uh-huh. 9 Q. And let's be specific, the one 10 that's referenced in paragraph 5 of Exhibit 1. 11 A. Okay. 12 Q. You said that after that meeting, 13 you initiated some sort of due diligence process. 14 Correct? 15 MS. McCLURE: Objection, form. 16 THE WITNESS: That's correct. 17 BY MR. PIFKO: 18 Q. Prior to that time, did you have 19 no due diligence process in place? 20 MS. McCLURE: Objection to form. 21 THE WITNESS: Yes, we had due 22 diligence. Yes. 23 BY MR. PIFKO: 24 Q. What due diligence process was in</p>

1 place before that meeting? 2 A. The same due diligence that we 3 had had in place for years. 4 Q. And what was it -- 5 A. Do you want me to describe it? 6 Q. Yes. 7 A. Our responsibility was to make a 8 good faith effort to make sure that that 9 customer's properly licensed with the state and 10 registered with DEA. 11 Q. Anything else? 12 A. No. 13 Q. So at that time of the meeting in 14 2005, the only due diligence that was in place 15 was a process to make sure that the customer was 16 properly licensed; is that correct? 17 MS. McCLURE: Objection, form. 18 THE WITNESS: Properly licensed 19 by the state and registered with DEA. 20 That was our requirement under the 21 federal regulations. 22 BY MR. PIFKO: 23 Q. How is it that AmerisourceBergen 24 missed these millions of orders in its suspicious	Page 74 1 THE WITNESS: No, I don't. 2 BY MR. PIFKO: 3 Q. Did you do anything other than 4 report these orders to -- some of the orders that 5 you discussed to DEA to prevent diversion? 6 MS. McCLURE: Objection, form. 7 THE WITNESS: Yes. 8 BY MR. PIFKO: 9 Q. What did you do? 10 A. We cut off -- I believe we cut 11 off some of these pharmacies, if not all of them. 12 I can't recall exactly which ones. 13 Q. Do you know how many you cut off? 14 A. Couldn't -- don't recall. 15 Q. Do you know when you cut them 16 off? 17 A. Either prior to the suspension or 18 after. 19 Q. So you cut some of them off maybe 20 after the suspension order? 21 MS. McCLURE: Objection, form. 22 THE WITNESS: Well, it would have 23 been prior, because we weren't able to 24 ship after -- after the suspension order.
1 order monitoring system, as discussed here in 2 Exhibit 1? 3 MS. McCLURE: Objection, form, 4 foundation. 5 THE WITNESS: I'm not sure we 6 missed them. I believe they were 7 reported to DEA as suspicious orders. 8 BY MR. PIFKO: 9 Q. It's your testimony that these 10 orders were picked up by the suspicious order 11 monitoring system and reported to DEA? 12 A. I'm not saying every one. I'm 13 just -- I know that, from what I recall, some of 14 these customers that were mentioned in here, as I 15 recall, had orders that were reported to DEA as 16 suspicious. 17 Q. Do you have any sense of the 18 percentage of the orders, if any, that were 19 caught? 20 A. No, I do not. 21 Q. If you reported these orders to 22 DEA, do you have any understanding as to why DEA 23 issued this order to show cause? 24 MS. McCLURE: Objection, form.	Page 75 1 So it would have been prior to that. 2 BY MR. PIFKO: 3 Q. Would that be contained in any 4 document? 5 MS. McCLURE: Objection, form. 6 THE WITNESS: I'm sure -- no, I 7 don't want to speculate. I don't know. 8 BY MR. PIFKO: 9 Q. Based on your -- you've been with 10 the company for over 30 years. Right? Longer? 11 A. Longer. 12 Q. 40 years? 13 A. Yes. 14 Q. Based on your knowledge of the 15 company's practices and procedures, if you cut 16 off a customer, where would that be documented? 17 MS. McCLURE: Objection, form. 18 THE WITNESS: It depends on what 19 system we're using to document things at 20 a specific time. We've changed 21 documentation processes over the years 22 many times. 23 BY MR. PIFKO: 24 Q. At the time of this order to show

<p>1 cause.</p> <p>2 MS. McCLURE: Objection, form.</p> <p>3 THE WITNESS: Again, I'm not sure</p> <p>4 where it would have been documented.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. You don't know if it would have</p> <p>7 been documented at all?</p> <p>8 MS. McCLURE: Objection, form,</p> <p>9 misstates the witness's prior testimony.</p> <p>10 THE WITNESS: I don't recall</p> <p>11 exactly.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. How about generally?</p> <p>14 A. Generally --</p> <p>15 MS. McCLURE: Same objection.</p> <p>16 THE WITNESS: Generally, I would</p> <p>17 say that they were documented somewhere.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Did you review anything in</p> <p>20 preparing for your deposition that would have</p> <p>21 discussed the company's shipments or orders</p> <p>22 from -- with respect to the pharmacies in</p> <p>23 Exhibit 1?</p> <p>24 MS. McCLURE: Objection, form.</p>	<p>Page 78</p> <p>1 THE WITNESS: I can't.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. You're unable to do that?</p> <p>4 A. Login to, which system are you</p> <p>5 talking about? Our business system?</p> <p>6 Q. AmerisourceBergen's diversion</p> <p>7 control systems.</p> <p>8 MS. McCLURE: Objection, form.</p> <p>9 THE WITNESS: No. I don't login</p> <p>10 to that.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Do members of your team login to</p> <p>13 that?</p> <p>14 MS. McCLURE: Objection, form.</p> <p>15 THE WITNESS: Not on my team, no.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Do you know who Eric Cherveny is?</p> <p>18 A. Yes, I do.</p> <p>19 Q. Is he someone that was under your</p> <p>20 team at any point?</p> <p>21 MS. McCLURE: Objection, form.</p> <p>22 THE WITNESS: He was under my</p> <p>23 team back in, you know, I can't</p> <p>24 remember -- in the 2005 to 2010, sometime</p>
<p>Page 79</p> <p>1 THE WITNESS: No, no.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. If you were going to do that, how</p> <p>4 would you do that?</p> <p>5 MS. McCLURE: Objection, form.</p> <p>6 THE WITNESS: How would I do</p> <p>7 what?</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. If you were going to research the</p> <p>10 order history --</p> <p>11 A. Uh-huh.</p> <p>12 Q. -- and shipments made to any of</p> <p>13 the customers discussed in Exhibit 1, how would</p> <p>14 you go about doing that?</p> <p>15 MS. McCLURE: Objection, form.</p> <p>16 THE WITNESS: I would go back to</p> <p>17 find out whatever system we were using to</p> <p>18 document and look through that and do a</p> <p>19 search.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. It's true that today you can log</p> <p>22 on to AmerisourceBergen's system and look back at</p> <p>23 customer histories and correspondence. Correct?</p> <p>24 MS. McCLURE: Objection, form.</p>	<p>Page 81</p> <p>1 in that area.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. If he testified that you could go</p> <p>4 back and look into AmerisourceBergen's systems</p> <p>5 and get ordering information and information</p> <p>6 about a customer's history going back at least as</p> <p>7 early as 2000, would you have any reason to</p> <p>8 disagree with him?</p> <p>9 MS. McCLURE: Objection, form.</p> <p>10 THE WITNESS: I'm not sure how</p> <p>11 you would, but maybe he can.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. With respect to these orders, you</p> <p>14 would have reported them after you shipped them.</p> <p>15 Correct?</p> <p>16 MS. McCLURE: Objection, form.</p> <p>17 THE WITNESS: Which orders are</p> <p>18 you talking about specifically?</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. The 5.2 million orders of</p> <p>21 hydrocodone products or dosage units discussed in</p> <p>22 Exhibit 1.</p> <p>23 MS. McCLURE: Objection to form.</p> <p>24 THE WITNESS: At that time, they</p>

<p style="text-align: right;">Page 82</p> <p>1 would have been reported after.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. None of these orders would have</p> <p>4 been reported prior to shipment. Correct?</p> <p>5 A. That's correct.</p> <p>6 Q. And all of these orders would</p> <p>7 have been shipped without any due diligence.</p> <p>8 Correct?</p> <p>9 MS. McCLURE: Objection, form.</p> <p>10 THE WITNESS: That's incorrect.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Other than checking their</p> <p>13 registration?</p> <p>14 MS. McCLURE: Objection, form.</p> <p>15 THE WITNESS: Checking the</p> <p>16 registration, the licensing and all the</p> <p>17 other due diligence that we do on</p> <p>18 customers, whether it's credit, their</p> <p>19 ability to pay and whatever else that</p> <p>20 our -- there's different -- other parts</p> <p>21 of our due diligence that are done. But</p> <p>22 as far as controlled substances, it was</p> <p>23 the licensing.</p> <p>24 BY MR. PIFKO:</p>	<p style="text-align: right;">Page 84</p> <p>1 decision would be made about that</p> <p>2 customer based on that due diligence.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. Right. But my point is, there's</p> <p>5 no specific due diligence that you conduct with</p> <p>6 respect to an order?</p> <p>7 A. To each order?</p> <p>8 MS. McCLURE: Objection to form.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Right.</p> <p>11 A. Not -- not for each specific</p> <p>12 order, no.</p> <p>13 Q. Okay. So the only due diligence</p> <p>14 that would have been conducted would have been a</p> <p>15 collecting of a form and reviewing that form and</p> <p>16 deciding as a general matter whether to do</p> <p>17 business with that customer. Correct?</p> <p>18 MS. McCLURE: Objection, form.</p> <p>19 THE WITNESS: That's -- that's</p> <p>20 incorrect. That's not correct.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. What's incorrect about my</p> <p>23 statement?</p> <p>24 A. Well, the due diligence is</p>
<p style="text-align: right;">Page 83</p> <p>1 Q. Okay. So the orders of the</p> <p>2 5.2 million dosage units that are discussed in</p> <p>3 Exhibit 1, the only due diligence with respect to</p> <p>4 diversion control that would have been performed</p> <p>5 on those would have been checking the licensing?</p> <p>6 MS. McCLURE: Objection, form,</p> <p>7 misstates the witness's prior testimony.</p> <p>8 THE WITNESS: Well, let me take</p> <p>9 you back, because actually, since 2005,</p> <p>10 after that meeting with DEA, we did put</p> <p>11 the due diligence process in place with</p> <p>12 questionnaires. And probably I'm sure a</p> <p>13 lot of these pharmacies had been -- had a</p> <p>14 due diligence investigation, had a</p> <p>15 questionnaire and a site visit.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. But that's something you</p> <p>18 conducted -- it's static.</p> <p>19 You conduct the -- you collect</p> <p>20 the questionnaire, and it sits in a file.</p> <p>21 Correct?</p> <p>22 MS. McCLURE: Objection, form.</p> <p>23 THE WITNESS: No. It gets</p> <p>24 reviewed. It would be reviewed, and a</p>	<p style="text-align: right;">Page 85</p> <p>1 just -- that due diligence questionnaire is just</p> <p>2 part of the process. So any -- an order that</p> <p>3 would have shown up on that suspicious order</p> <p>4 report would have prompted a due diligence</p> <p>5 investigation --</p> <p>6 MS. McCLURE: Objection. Sorry.</p> <p>7 THE WITNESS: -- and a site</p> <p>8 visit.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. So I'm getting mixed statements</p> <p>11 from you.</p> <p>12 You said that there was no</p> <p>13 specific due diligence with respect to an order;</p> <p>14 is that correct?</p> <p>15 A. Well, that due diligence could</p> <p>16 have been prompted by an order.</p> <p>17 Q. Explain that to me.</p> <p>18 A. Okay. So when we -- when we</p> <p>19 started doing the questionnaires, the basis for</p> <p>20 doing those questionnaires would have been that</p> <p>21 possible excessive and suspicious order report,</p> <p>22 and that's when that would prompt that</p> <p>23 questionnaire. So it is related to -- it would</p> <p>24 have been related to an order.</p>

	Page 86		Page 88
1	Q. How frequently --	1	Q. Every time?
2	A. Or a customer's history.	2	A. I'm assuming it would, yes.
3	Q. How frequently would you collect	3	Q. So every time AmerisourceBergen
4	this form from a customer?	4	had a suspicious order at the time of the
5	MS. McCLURE: Objection, form.	5	issuance of this order to show cause and before,
6	THE WITNESS: I don't know.	6	every single time, for every customer, it would
7	BY MR. PIFKO:	7	7 have triggered a due diligence investigation?
8	Q. For every single order that they	8	A. I don't know that. I don't know
9	would place that would be suspicious, you would	9	that for sure.
10	collect another form?	10	Q. You don't know that?
11	MS. McCLURE: Objection, form.	11	A. I don't know that.
12	THE WITNESS: I don't know.	12	Q. Do you have any specific
13	BY MR. PIFKO:	13	understanding of how AmerisourceBergen's due
14	Q. Was it -- well, you were in	14	diligence process worked --
15	charge of diversion control practices at the	15	MS. McCLURE: Objection to form.
16	time. Correct?	16	BY MR. PIFKO:
17	MS. McCLURE: Objection, form.	17	Q. -- at that time and before?
18	THE WITNESS: I oversaw that	18	A. I've already answered that.
19	area. That's part of regulatory at the	19	Q. Well, I'm trying to understand
20	time, yes.	20	what would trigger a due diligence investigation.
21	BY MR. PIFKO:	21	You don't seem to know.
22	Q. And you don't know how the due	22	MS. McCLURE: Objection,
23	diligence process worked?	23	misstates the witness's testimony, asked
24	MS. McCLURE: Objection, form,	24	and answered, form.
	Page 87		Page 89
1	asked and answered.	1	THE WITNESS: As I recall, a due
2	THE WITNESS: Yes. I already	2	diligence investigation would have been
3	explained that to you.	3	prompted by customers showing up on that
4	BY MR. PIFKO:	4	suspicious order report, that possible
5	Q. Well, I'm asking you questions,	5	excessive and suspicious orders I think
6	and you're saying you don't know.	6	is what it's called. That would prompt
7	A. Well, I don't know if it was done	7	that due diligence to be done.
8	on every single order.	8	Would it be done every single
9	Q. Okay.	9	time an order would hit that? I don't
10	A. I couldn't tell you. It may have	10	know. I don't recall.
11	been.	11	BY MR. PIFKO:
12	Q. But that's something that you	12	Q. Would you have investigated that
13	don't seem to know about the system. Agree?	13	order specifically, or would you just look at the
14	MS. McCLURE: Objection, form.	14	customer?
15	THE WITNESS: Ask the question	15	MS. McCLURE: Objection to form.
16	again? I'm sorry.	16	THE WITNESS: We mainly would
17	BY MR. PIFKO:	17	look at the customer.
18	Q. Well, I'm trying to understand if	18	BY MR. PIFKO:
19	AmerisourceBergen had an order that was	19	Q. And what would the nature of your
20	suspicious, whether that order triggered a	20	customer inquiry be?
21	specific due diligence inspection of the order.	21	MS. McCLURE: Objection, form.
22	A. If it -- if that -- if that order	22	THE WITNESS: The nature would be
23	showed up on a suspicious order report, it would	23	a site visit and completion of a
24	have triggered a due diligence investigation.	24	questionnaire.

Page 90	Page 92
<p>1 BY MR. PIFKO:</p> <p>2 Q. So did this prompt any changes to</p> <p>3 AmerisourceBergen's suspicious order monitoring</p> <p>4 system?</p> <p>5 MS. McCLURE: Objection, form.</p> <p>6 THE WITNESS: Did what prompt?</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. This order to show cause.</p> <p>9 A. Oh, yes, yes.</p> <p>10 Q. That resulted in a settlement</p> <p>11 agreement with DEA. Correct?</p> <p>12 MS. McCLURE: Objection, asked</p> <p>13 and answered.</p> <p>14 THE WITNESS: Yes.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. What were the nature of the</p> <p>17 changes that you instituted after this?</p> <p>18 MS. McCLURE: Objection, form.</p> <p>19 And objection, asked and answered.</p> <p>20 THE WITNESS: We enhanced our</p> <p>21 suspicious order monitoring program at</p> <p>22 the direction of DEA. They wanted us to</p> <p>23 develop a system that would stop and hold</p> <p>24 an order and determine whether it was</p>	<p>1 Do you see that?</p> <p>2 A. Yes, I do.</p> <p>3 Q. You are talking about attending</p> <p>4 an HDMA conference. Agreed?</p> <p>5 A. Agree.</p> <p>6 Q. It says, "The HDMA DMC agenda."</p> <p>7 Do you see that?</p> <p>8 A. Yes, I do.</p> <p>9 Q. What's the HDMA DMC?</p> <p>10 A. HDMA DMA is a distribution</p> <p>11 management conference. It's an annual conference</p> <p>12 that HDMA conducts.</p> <p>13 Q. The subject of this email is</p> <p>14 "Big Four' DEA Strategy Discussion 2."</p> <p>15 Do you see that?</p> <p>16 A. Yes.</p> <p>17 Q. So you're reaching out to, at</p> <p>18 this time, people from McKesson, Cardinal Health</p> <p>19 and HD Smith to have a big four DEA strategy</p> <p>20 discussion. Correct?</p> <p>21 MS. McCLURE: Objection, form.</p> <p>22 THE WITNESS: It's what it says,</p> <p>23 yeah, yeah.</p> <p>24 BY MR. PIFKO:</p>
<p>1 suspicious before shipping it.</p> <p>2 - - -</p> <p>3 (Deposition Exhibit No. Mays</p> <p>4 V2-2, Email chain, top one dated 3 Mar</p> <p>5 2013, Bates stamped ABDCMDL00378483</p> <p>6 through ABDCMDL00378488, was marked for</p> <p>7 identification.)</p> <p>8 - - -</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Handing you what's marked as Mays</p> <p>11 Volume 2, Exhibit 2.</p> <p>12 For the record, it's an email</p> <p>13 thread labeled ABDCMDL00378483 through 88.</p> <p>14 Let me know when you're done,</p> <p>15 take a moment to review that.</p> <p>16 A. (Reviewing document.)</p> <p>17 Okay.</p> <p>18 Q. Right. If you go to the second</p> <p>19 to last page here.</p> <p>20 A. Okay.</p> <p>21 Q. It's the start of -- well, it's</p> <p>22 an email -- that part of the header is on the</p> <p>23 prior page, but it's an email from you to people</p> <p>24 at Cardinal Health, McKesson and HD Smith.</p>	<p>1 Page 91</p> <p>2 Q. Why were you reaching out to</p> <p>3 representatives from this company -- these</p> <p>4 companies to have a DEA strategy discussion at</p> <p>5 this time?</p> <p>6 A. I think we would typically get</p> <p>7 together sometime around those -- those</p> <p>8 conferences, because it was about the only time</p> <p>9 of the year we had face-to-face time. And we</p> <p>10 would just talk about common concerns and issues</p> <p>11 that we have and do some benchmarking, share</p> <p>12 ideas about how we can improve our programs.</p> <p>13 Q. When you say programs and</p> <p>14 concerns, you're talking about specifically in</p> <p>15 the diversion control area. Correct?</p> <p>16 A. No. It could be anything</p> <p>17 regulatory, not just diversion. It could be</p> <p>18 things about, you know, sometimes we would talk</p> <p>19 about DEA inspections and how they -- how they're</p> <p>20 handled, just to get some -- help each other out.</p> <p>21 Q. Okay. But what I'm trying to ask</p> <p>22 is, when you were talking about concerns and</p> <p>23 benchmarking and programs, you're talking about</p> <p>24 programs that relate to DEA compliance. Correct?</p> <p>25 A. I think for the most part. It's</p>

<p style="text-align: right;">Page 94</p> <p>1 basically anything regulatory that we could talk 2 about. 3 Q. And these other people at 4 McKesson, Cardinal Health and HD Smith, they all 5 had similar responsibilities for regulatory and 6 compliance issues like you did? 7 MS. McCLURE: Objection to form. 8 THE WITNESS: For the most part 9 as I recall, yes.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. So this was -- this specific 12 subject line says, "Strategy Discussion 2." 13 Do you see that?</p> <p>14 A. Yeah.</p> <p>15 Q. So this was -- and as you just 16 testified, this was something that you regularly 17 did in connection with HDMA meetings that 18 occurred annually?</p> <p>19 MS. McCLURE: Objection to form. 20 THE WITNESS: Not always. I 21 think we'd met before. Might not have 22 been at an HDA meeting.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. But you had, with some degree of</p>	<p style="text-align: right;">Page 96</p> <p>1 A. No, I don't believe it was. 2 Q. What was your recollection that 3 brought you all to Chicago? 4 A. I think it had been after, you 5 know, the companies -- you know, we had had 6 action taken against us and I think Cardinal and 7 I'm not sure if McKesson had at the time. And I 8 think the idea was just to get together and see 9 how we could do things better. 10 Q. You think that would have been in 11 2007 or '8? 12 MS. McCLURE: Objection. 13 THE WITNESS: I don't think so. 14 I think it might have been after that. I 15 don't know.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. What action had been taken 18 against you that you're recalling?</p> <p>19 A. The suspension that we were 20 previously talking about. 21 Q. And you recall that Cardinal had 22 had some action taken against it around the time 23 of this meeting as well?</p> <p>24 A. Yeah.</p>
<p style="text-align: right;">Page 95</p> <p>1 regularity, meetings with these people to discuss 2 regulatory and compliance issues?</p> <p>3 MS. McCLURE: Objection, form. 4 THE WITNESS: I wouldn't say 5 regularity. We only met like that maybe 6 two or three times.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. When was the first time you had 9 such a meeting like that?</p> <p>10 A. I can't remember if it was before 11 this one or after this one. We met in Chicago at 12 the airport one time. And I think Cardinal 13 hosted that meeting.</p> <p>14 Q. Do you have a rough idea about 15 when that was?</p> <p>16 MS. McCLURE: Objection. 17 THE WITNESS: No, I don't. 18 MS. McCLURE: Asked and answered.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. But it was a meeting in Chicago 21 at the airport?</p> <p>22 A. I believe it was, yeah.</p> <p>23 Q. Was that in connection with an 24 HDMA conference?</p>	<p style="text-align: right;">Page 97</p> <p>1 Q. What specifically was the nature 2 of your understanding about the action taken 3 against Cardinal at that time?</p> <p>4 A. The one -- the meeting in 5 Chicago? That was when -- because I remember the 6 guy was at that meeting, Michael Mone from 7 Cardinal. And he got called during the meeting, 8 and he had to leave. And I think it was when 9 they had their -- one of their registrations 10 suspended or something and he had to leave. We 11 didn't know what it was about, but he had to just 12 leave all of a sudden.</p> <p>13 Q. Okay. Do you have a rough idea 14 on or around the time that was?</p> <p>15 A. No, I don't.</p> <p>16 Q. Did that -- your recollection 17 lead to a fine against Cardinal Health?</p> <p>18 MS. McCLURE: Objection, form. 19 THE WITNESS: I think it did 20 after that, but I'm not -- I don't -- 21 because it seems like they had a couple. 22 And I'm not sure if both resulted in 23 fines.</p> <p>24 BY MR. PIFKO:</p>

Page 98	Page 100
<p>1 Q. Okay. And then you know you had 2 this meeting that's reflected in Exhibit 2. 3 Correct?</p> <p>4 A. Uh-huh.</p> <p>5 Q. And then you believe there was 6 another meeting that you recall. Correct?</p> <p>7 A. The one at HDA, the one at HDMA 8 and then the one in Chicago. I think that was 9 all. There may have been another one.</p> <p>10 Q. You think there was another one?</p> <p>11 MS. McCLURE: Objection to form.</p> <p>12 THE WITNESS: I may be thinking 13 about the same one, the one at the HDA 14 meeting, that -- it's the two that I can 15 recall specifically, yeah.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. This meeting reflected in 18 Exhibit 2, this was a meeting that was ultimately 19 held. Correct?</p> <p>20 A. You know, I don't remember the 21 meeting itself, whether we actually had it or 22 not. I'm -- I don't want to assume, but --</p> <p>23 Q. Where was this?</p> <p>24 A. -- it looks like we planned to</p>	<p>1 2/6/2008, Bates stamped 2 CAH_MDL2804_01364805 through 3 CAH_MDL2804_01364809, was marked for 4 identification.) 5 - - - 6 BY MR. PIFKO: 7 Q. Handing you what's marked as Mays 8 Volume 2 Exhibit 3. 9 For the record, this is a 10 Cardinal Health document Bates labeled 11 CAH_MDL2804_01364805 to 809. 12 Take a moment to review this and 13 let me know when you're ready.</p> <p>14 A. Okay.</p> <p>15 (Reviewing document.)</p> <p>16 Okay.</p> <p>17 Q. Have you seen this before?</p> <p>18 A. I don't recall it.</p> <p>19 Q. You see at the top it's an email 20 from you to Steve Reardon?</p> <p>21 A. Yes, I do.</p> <p>22 Q. Dated February 6, 2008?</p> <p>23 A. Yes, I see that.</p> <p>24 Q. It's discussing a Bloomberg story</p>
<p>1 get together, but I just don't remember the 2 meeting specifically.</p> <p>3 Q. Where was this meeting?</p> <p>4 A. I saw something in the email 5 about me having tickets to Phillies spring 6 training, so I believe that was when the 7 conference was in Tampa.</p> <p>8 Q. Okay.</p> <p>9 A. The HDA conference was in Tampa.</p> <p>10 Q. And then you talk about in this 11 email about scheduling a dinner with them as 12 well?</p> <p>13 MS. McCLURE: Objection to form.</p> <p>14 THE WITNESS: Yeah. I just don't 15 recall who went to dinner or not. I just 16 don't remember that.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Do you think that you had other 19 meetings with these individuals in subsequent HDA 20 conferences?</p> <p>21 A. I don't recall.</p> <p>22 - - -</p> <p>23 (Deposition Exhibit No. Mays 24 V2-3, Email chain, top one dated</p>	<p>Page 99</p> <p>1 about McKesson negotiating shipping restrictions 2 as part of a DEA probe. Agree?</p> <p>3 A. Yeah. Yes, I agree.</p> <p>4 Q. You forwarded this article to 5 Steve Reardon at Cardinal Health. Agree?</p> <p>6 A. That's what it looks like, yes.</p> <p>7 Q. Who is Steve Reardon?</p> <p>8 A. He was my counterpart at Cardinal 9 at the time.</p> <p>10 Q. And you thought that he would be 11 interested to see this article about McKesson?</p> <p>12 MS. McCLURE: Objection, form.</p> <p>13 THE WITNESS: I would think so.</p> <p>14 That would be the only reason I would 15 have sent it to him.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. You had a practice of exchanging 18 information with Mr. Reardon about diversion 19 control issues?</p> <p>20 MS. McCLURE: Objection, form.</p> <p>21 THE WITNESS: No.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. Why do you believe you would have 24 shared this with him on this occasion?</p>

Page 102		Page 104
1 MS. McCLURE: Objection to form.		1 record at 1:00 p.m.
2 THE WITNESS: I don't recall.		2 (Witness excused.)
3 This was 11 years ago. I don't remember		3 (Deposition concluded at
4 why I sent it to him.		4 approximately 1:00 p.m.)
5 BY MR. PIFKO:		5
6 Q. Did you have regular	6	
7 communications with Steve Reardon?	7	
8 MS. McCLURE: Objection, form.	8	
9 THE WITNESS: Well, how -- define	9	
10 regular. Every day, every week, every	10	
11 month, every year?	11	
12 BY MR. PIFKO:	12	
13 Q. With any degree of regularity.	13	
14 MS. McCLURE: Objection to the	14	
15 definition.	15	
16 THE WITNESS: What's regularity?	16	
17 BY MR. PIFKO:	17	
18 Q. What's regular to you?	18	
19 A. Regular would be every day.	19	
20 Q. Did you talk to Steve Reardon	20	
21 with some frequency?	21	
22 MS. McCLURE: Objection to form.	22	
23 THE WITNESS: I would say	23	
24 occasionally, at HDA calls, HDA meetings,	24	
Page 103		Page 105
1 things like that. Not a lot of back and	1	
2 forth, no.	2	CERTIFICATE
3 BY MR. PIFKO:	3	
4 Q. From time to time you would share	4	
5 information, though, with him about issues in the	5	I HEREBY CERTIFY that the witness
6 drug distribution business. Correct?	6	was duly sworn by me and that the deposition is a
7 A. Yes. As long as it was not	7	true record of the testimony given by the
8 proprietary information from ABC.	8	witness.
9 MR. PIFKO: Go off the record for	9	It was requested before
10 a minute.	10	completion of the deposition that the witness,
11 THE VIDEOGRAPHER: Going off the	11	STEPHEN MAYS, have the opportunity to read and
12 record, 12:56 p.m.	12	sign the deposition transcript.
13 - - -	13	
14 (A recess was taken from	14	ANN MARIE MITCHELL, a Federally
15 12:56 p.m. to 1:00 p.m.)	15	Approved Certified Realtime
16 - - -	16	Reporter, Registered Diplomate
17 THE VIDEOGRAPHER: Back on record	17	Reporter, Registered Merit Reporter and
18 at 1:00 p.m.	18	Notary Public
19 MR. PIFKO: All right. We don't	19	(The foregoing certification of
20 have any further questions at this time.	20	this transcript does not apply to any
21 MS. McCLURE: No further -- no	21	reproduction of the same by any means, unless
22 questions.	22	under the direct control and/or supervision of
23 THE VIDEOGRAPHER: This ends	23	the certifying reporter.)
24 today's deposition. We're going off the	24	

